Neoprobe loses Nasdaq listing as prospects look poor
This article was originally published in Clinica
Executive Summary
Neoprobe, a US cancer diagnostic company which has suffered from a lack of funding and the failure to find a partner for its radioimmunoguided surgery (RIGS) technique, has been delisted from Nasdaq. The company will trade on the over-the-counter bulletin board.